-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AFM-24I in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AFM-24I in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AFM-24I in Colorectal Cancer Drug Details: AFM-24I is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AFM-24I in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AFM-24I in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AFM-24I in Solid Tumor Drug Details: AFM-24I is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AFM-24I in Transitional Cell Cancer (Urothelial Cell Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AFM-24I in Transitional Cell Cancer (Urothelial Cell Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AFM-24I in Transitional Cell Cancer (Urothelial Cell...
-
Product Insights
NewNet Present Value Model: Kymera Therapeutics Inc’s KT-333
Empower your strategies with our Net Present Value Model: Kymera Therapeutics Inc's KT-333 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Thematic Analysis
NewMining M&A Deals, Q1 2024 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q1 2024 in the Mining Sector
-
Company Insights
NewGenfit SA Pipeline Insight and Competitive Landscape, 2024
Empower your strategies with our Genfit SA Pipeline Insight and Competitive Landscape, 2024 report and make more profitable business decisions. Genfit SA (Genfit) is a late-stage biopharmaceutical company. It develops therapeutic and diagnostic solutions for metabolic and inflammatory diseases in liver and gastroenterology diseases. The company’s pipeline products include VS-01-ACLF, nitazoxanide (NTZ), inhibitor SRT-015, CLM-022, VS-02-HE, GNS561, VS-01-HAC, TS-01 and NIS2+. Genfit's products are used in various therapeutic areas including acute-on-chronic liver failure (ACLF), hepatic encephalopathy (HE), cholangiocarcinoma (CCA), urea...
-
Product Insights
NewQuarterly Still Wine pricing trends in the United States
Empower your strategies with our Quarterly Still Wine pricing trends in the United States report and make more profitable business decisions. Consumers’ preferences for stores are most heavily influenced by pricing and promotions, but brands and retailers continue to adjust prices and promotions based on insufficient information from expensive, drawn-out, and incomplete audits of rival techniques. Brands and retailers can benefit from the unique intelligence provided by GlobalData Ecommerce Price Tracker, covering millions of SKUs, to identify, anticipate, and implement...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CBP-1019 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CBP-1019 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CBP-1019 in Colorectal Cancer Drug Details: CBP-1019 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Linavonkibart in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Linavonkibart in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Linavonkibart in Head And Neck Squamous...
-
Product Insights
New3D Systems Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our 3D Systems Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. 3D Systems Inc delivers manufacturing solutions and expertise to applications and industries. The company is headquartered in Rock Hill, South Carolina, the US. GlobalData's Medical Devices company profile report, “3D Systems Inc Pipeline Insight and Competitive Landscape, 2023" provides information about the company overview and analysis on their pipeline products. This company profile report provides key information and data...